Searched for: author%3A%22Philippens%2C+I.H.C.H.M.%22
(1 - 20 of 21)

Pages

document
Philippens, I.H.C.H.M. (author), Joosen, M.J.A. (author), Ahnaou, A. (author), Andres, I. (author), Drinkenburg, W.H.I.M. (author)
Current dopamine replacement therapies, in Parkinson's disease (PD), result in aversive side effects and rapid drug dose escalation over time. Therefore, a non-dopaminergic treatment would be an advantageous supplement to lower the dose of dopamine replacement treatment postponing the occurrence of side effects. The noradrenergic system plays an...
article 2014
document
Verhave, P.S. (author), Jongsma, M.J. (author), van den Berg, R.M. (author), Vanwersch, R.A.P. (author), Smit, A.B. (author), Philippens, I.H.C.H.M. (author)
The present study evaluates neuroprotection in a marmoset MPTP (1-methyl-1,2,3,6-tetrahydropyridine) model representing early Parkinson's disease (PD). The anti-glutamatergic compound riluzole is used as a model compound for neuroprotection. The compound is one of the few protective compounds used in the clinic for a neurodegenerative disorder....
article 2012
document
Verhave, P.S. (author), Jongsma, M.J. (author), van den Berg, R.M. (author), Vis, J.C. (author), Vanwersch, R.A.P. (author), Smit, A.B. (author), van Someren, E.J.W. (author), Philippens, I.H.C.H.M. (author)
Study Objectives: Sleep problems are a common phenomenon in most neurological and psychiatric diseases. In Parkinson disease (PD), for instance, sleep problems may be the most common and burdensome non-motor symptoms in addition to the well-described classical motor symptoms. Since sleep disturbances generally become apparent in the disease...
article 2011
document
van Helden, H.P.M. (author), Joosen, M.J.A. (author), Philippens, I.H.C.H.M. (author)
The rapid onset of toxic signs following nerve agent intoxication and the apprehension that current therapy (atropine, oxime, diazepam) may not prevent brain damage, requires supportive pretreatment. Since the current pretreatment drug pyridostigmine fails in protecting brain-AChE, more effective pretreatment is necessary.A main focus of present...
article 2011
document
Verhave, P.S. (author), Vanwersch, R.A.P. (author), Helden, H.P.M. (author), Smit, A.B. (author), Philippens, I.H.C.H.M. (author), TNO Defensie en Veiligheid (author)
The validity of the common marmoset (Callithrix jacchus) as a model for human disease depends on the development of parameters with clinical relevance. We tested the effect of treatment with MPTP in two newly developed non-invasive motor behavioral paradigms in the context of Parkinson's disease. The "Tower" was designed to quantify the marmoset...
article 2009
document
TNO Defensie en Veiligheid (author), van Vliet, S.A.M. (author), Vanwersch, R.A.P. (author), Jongsma, M.J. (author), Olivier, B. (author), Philippens, I.H.C.H.M. (author)
Current therapies for Parkinson's disease (PD) like l-dopa and dopamine (DA) agonists have declined efficacy after long term use. Therefore, research towards supplementary or alternative medication is needed. The implementation in PD can be expedited by application of compounds already used in the clinic. In this study the therapeutic effects of...
article 2008
document
TNO Defensie en Veiligheid (author), van Vliet, S.A.M. (author), Jongsma, M.J. (author), Vanwersch, R.A.P. (author), Olivier, B. (author), Philippens, I.H.C.H.M. (author)
article 2008
document
TNO Defensie en Veiligheid (author), Philippens, I.H.C.H.M. (author), Jongsma, M.J. (author), Joosen, M.J.A. (author), Bouwman, G. (author), Vanwersch, R.A.P. (author)
Compounds with another mechanism of action than enzyme inhibition alone were tested in their capability to counteract or prevent incapacitation and lethality after 2xLD50 soman when used as a pretreatment or as a post-intoxication therapy in guinea pigs. To increase the validity of extrapolating data to man, crucial experiments were performed in...
conference paper 2007
document
van Erp, J.B.F. (author), Duistermaat, M. (author), Philippens, I.H.C.H.M. (author), van Veen, H.A.H.C. (author), Werkhoven, P.J. (author), TNO Defensie en Veiligheid (author)
Brain Machine Interfaces (BMIs) enable direct communication between the brain or nervous system and a machine without involving the sensory-motor system. BMIs are an embryonic technology and remarkable accomplishments have recently been reported. BMIs have a high potential and possibly an enormous impact on society, and may evoke a revolution in...
conference paper 2006
document
Philippens, I.H.C.H.M. (author), Jongsma, M.J. (author), Vanwersch, R.A. (author), TNO Defensie en Veiligheid (author)
The efficacy against lethality and post-intoxication incapacitation after 2x LD50 soman of different subacute pretreatment scenarios of 12 days was tested with or without post-intoxication therapy in guinea pigs. These pretreatment regimes were 1) the currently used pyridostigmine (PYR, 0.04 mg/kg/hr), 2) the combination of physostigmine (PHY, 0...
conference paper 2006
document
TNO Defensie en Veiligheid (author), van Vliet, S.A.M. (author), Vanwersch, R.A.P. (author), Jongsma, M.J. (author), van der Gugten, J. (author), Olivier, B. (author), Philippens, I.H.C.H.M. (author)
The vigilance-enhancing agent modafinil has neuroprotective properties: it prevents striatal ischemic injury, nigrostriatal pathway deterioration after partial transsection and intoxication with 1-methyl-1,2,3,6-tetrahydropyridine. The present study determines the protective effects of modafinil in the marmoset 1-methyl-1,2,3,6...
article 2006
document
TNO Defensie en Veiligheid (author), van Vliet, S.A.M. (author), Jongsma, M.J. (author), Vanwersch, R.A.P. (author), Olivier, B. (author), Philippens, I.H.C.H.M. (author)
Rationale: Modafinil is increasingly used in sleep disturbances in general and in neurodegenerative diseases and is recently being used in healthy people for attention control. However, the application of modafinil is possibly not only restricted to alertness enhancing effects. More insight in this compound may lead to new applications. Not all...
article 2006
document
TNO Defensie en Veiligheid (author), Philippens, I.H.C.H.M. (author), Joosen, M.J.A. (author), Vanwersch, R.A.P. (author)
During military operations, soldiers may be exposed to mixtures of chemicals and to physical, emotional and psychological stress factors, which all may influence efficacy of any treatment, including the nerve agent pretreatment regimen. The purpose of this study was therefore to investigate the influence of chronic intermittent, variable,...
article 2005
document
Philippens, I.H.C.H.M. (author), Jongsma, M.J. (author), Vanwersch, R.A.P. (author), Prins Maurits Laboratorium TNO (author)
The efficacy against lethality and post-intoxication incapacitation after 2x LD50 soman of different subacute pretreatment scenarios of 12 days was tested with or without post-intoxication therapy in guinea pigs. These pretreatment regimes were 1) the currently used pretreatment with pyridostigmine (PYR, 0.04 mg/kg/hr), 2) the combination of...
conference paper 2004
document
de Groot, D.M.G. (author), Bierman, E.P.B. (author), Bruijnzeel, P.L.B. (author), Carpentier, P. (author), Kulig, B.M. (author), Lallement, G. (author), Melchers, B.P.C. (author), Philippens, I.H.C.H.M. (author), van Huygevoort, A.H.B.M. (author)
Poisoning with the potent nerve agent soman produces a cascade of central nervous system (CNS) effects characterized by severe convulsions and eventually death. In animals that survive a soman intoxication, lesions in the amygdala, piriform cortex, hippocampus and thalamus can be observed. In order to examine the mechanisms involved in the...
article 2001
document
Philippens, I.H.C.H.M. (author), Joosen, M.J.A. (author), Groen, B. (author), Vanwersch, R.A.P. (author), Busker, R.W. (author), Nieuwenhuizen, M.S. (author)
During research efforts towards finding effective drugs are performed in a standard laboratory situation. However, in a more realistic situation other factors may interfere with the treatment regime. There is growing evidence that stress occurring during military operations can impair the efficacy and appearance of side effects of medical...
conference paper 2001
document
Prins Maurits Laboratorium TNO (author), Philippens, I.H.C.H.M. (author)
doctoral thesis 1998
document
TNO Pharma (author), Melchers, B.P.C. (author), Philippens, I.H.C.H.M. (author), Wolthuis, O.L. (author)
The therapeutic efficacy of the oximes HI-6 and HLo-7 (132.5 μmol/kg), in combination with atropine, in soman- or tabun-intoxicated guinea pigs was compared, particularly with respect to recovery of shuttlebox performance and electroencephalograms (EEGs). After 1.5 x LD50 soman SC, therapy with HI-6 or HLo-7 resulted in survival of 87.5% of the...
article 1994
document
Philippens, I.H.C.H.M. (author), Melchers, B.P.C. (author), de Groot, D.M.G. (author), Wolthuis, O.L. (author)
It is known that rats poisoned with near-lethal doses of pinacolyl methylphosphonofluoridate (soman) develop brain lesions, particularly when convulsions are induced. When rats were intoxicated with a LD50 of soman and treated immediately thereafter with a combination of low doses of atropine and diazepam (LOW AS/DZ treatment), large decrements...
article 1992
document
Philippens, I.H.C.H.M. (author), Melchers, B.P.C. (author), Wolthuis, O.L. (author)
Behavioral training of guinea pigs by conventional methods, such as used for rats and mice, appears difficult. Hence, only a few behavioral experiments with guinea pigs have been described in the literature. An active avoidance technique in an automated two-way shuttlebox is described using sound as a conditioned (CS) and a tactile stimulus (a...
article 1992
Searched for: author%3A%22Philippens%2C+I.H.C.H.M.%22
(1 - 20 of 21)

Pages